News
BDXA
0.0000
0.00%
0.00
BD SAYS CEO PAY RATIO FOR 2024 WAS 396 TO 1
Reuters · 4d ago
BD SAYS CEO THOMAS POLEN'S 2024 TOTAL COMPENSATION WAS $17.3 MLN - SEC FILING
Reuters · 4d ago
BECTON DICKINSON AND CO - NOT UPDATING FISCAL 2025 GUIDANCE DUE TO SETTLEMENT
Reuters · 12/16 21:32
BD RESOLVES PREVIOUSLY DISCLOSED SEC INVESTIGATION
Reuters · 12/16 21:32
U.S. SEC SAYS BECTON DICKINSON TO PAY $175 MILLION FOR MISLEADING INVESTORS ABOUT ALARIS INFUSION PUMP
Reuters · 12/16 21:28
BRIEF-Maravai Lifesciences Appoints R. Andrew Eckert As Chairman Of The Board Of Directors
Reuters · 12/05 21:33
BECTON, DICKINSON AND COMPANY <BDX.N>: WELLS FARGO CUTS TARGET PRICE TO $275 FROM $280
Reuters · 11/08 11:32
U.S. RESEARCH ROUNDUP-Bath & Body Works, Datadog, Savers Value Village
Reuters · 11/08 07:30
BUZZ-U.S. STOCKS ON THE MOVE-BorgWarner, Digital Realty, Take-Two
Reuters · 11/07 19:04
BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, CoreCivic, WK Kellogg
Reuters · 11/07 15:52
Becton Dickinson and Co reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07 14:42
BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, AppLovin, Sarepta
Reuters · 11/07 14:22
BUZZ-Becton Dickinson climbs after Q4 results beat
Reuters · 11/07 13:18
BD SHARES UP 2.5% PREMARKET AFTER Q4 RESULTS BEAT
Reuters · 11/07 13:09
Becton Dickinson beats quarterly estimates on strength in drug-delivery devices
Reuters · 11/07 12:40
BRIEF-Becton Dickinson Q4 Adjusted EPS USD 3.81 Vs. IBES Estimate USD 3.77
Reuters · 11/07 11:30
BD - ISSUES FY25 REVENUE GUIDANCE INCLUDING GAAP GROWTH OF 8.9% TO 9.4%, ADJUSTED CURRENCY-NEUTRAL GROWTH OF 8.8% TO 9.3%
Reuters · 11/07 11:30
BD OUTLOOK FY 2025 GAAP REV $21.9 TO $22.1 BLN
Reuters · 11/07 11:30
More
Webull provides a variety of real-time BDXA stock news. You can receive the latest news about BECTON DICKINSON through multiple platforms. This information may help you make smarter investment decisions.
About BDXA
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.